CompletedPhase 1NCT01164163
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
Studying Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Mignon Loh, MD, MDUniversity of California, San Francisco
- Intervention
- ruxolitinib phosphate(drug)
- Enrollment
- 49 enrolled
- Eligibility
- 1-21 years · All sexes
- Timeline
- 2010
Study locations (24)
- UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
- Children's Hospital of Orange County, Orange, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- Children's Hospital Colorado Center for Cancer and Blood Disorders, Aurora, Colorado, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
- Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
- Riley's Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
- Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States
- Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
- Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis, Missouri, United States
- Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
- +9 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01164163 on ClinicalTrials.govOther trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2)
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05031897Two Step Haplo With Radiation ConditioningThomas Jefferson University
- ACTIVE NOT RECRUITINGPHASE2NCT04188405Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02530034Hu8F4 in Treating Patients With Advanced Hematologic MalignanciesM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03630991Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing ChemotherapyM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT03147612Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE2NCT02861417Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell TransplantM.D. Anderson Cancer Center
See all trials for Acute myeloid leukemia with t(9;22)(q34.1;q11.2) →